Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
Company Growth (employees)
Type
Public
HQ
Danvers, US
Size (employees)
908 (est)+22%
ABIOMED is headquartered in Danvers, US

ABIOMED Office Locations

ABIOMED has offices in Danvers and Aachen
Danvers, US (HQ)
22 Cherry Hill Dr
Aachen, DE
3 Neuenhofer Weg

ABIOMED Data and Metrics

ABIOMED Financial Metrics

ABIOMED's revenue was reported to be $445.3 m in FY, 2017
USD

Revenue (FY, 2017)

445.3 m

Revenue growth (FY, 2016 - FY, 2017), %

35%

Net income (FY, 2017)

52.1 m

EBIT (FY, 2017)

90.1 m

Market capitalization (15-Aug-2017)

7 b

Cash (31-Mar-2017)

39 m
ABIOMED's current market capitalization is $7 b.
USDFY, 2014FY, 2015Y, 2016FY, 2017

Revenue

183.6 m230.3 m329.5 m445.3 m

Revenue growth, %

25%43%35%

Gross profit

146.3 m190.4 m

Gross profit Margin, %

80%83%

R&D expense

66.4 m

General and administrative expense

218.2 m

Operating expense total

138 m161.7 m264.4 m355.2 m

EBIT

8.4 m28.7 m65.1 m90.1 m

EBIT margin, %

5%12%20%20%

Pre tax profit

8.5 m28.8 m65.8 m91.3 m

Income tax expense

1.2 m(84.9 m)27.7 m39.2 m

Net Income

7.4 m113.7 m38.1 m52.1 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Revenue

48.8 m51.9 m62 m73.4 m76.4 m85.8 m103 m103 m114.7 m

R&D expense

9.1 m8.7 m8.4 m10.2 m11.6 m13.8 m15.7 m18.1 m16.3 m

General and administrative expense

31.6 m29.5 m30.1 m37.3 m39.8 m41.9 m51 m53.1 m53.9 m

Operating expense total

40.7 m38.1 m38.5 m47.5 m51.4 m55.6 m66.7 m71.1 m70.3 m

EBIT

(1.5 m)4.2 m13.7 m15 m12.8 m17.4 m21.2 m14.5 m25.4 m

EBIT margin, %

(3%)8%22%20%17%20%21%14%22%

Pre tax profit

4.2 m13.7 m15.1 m13 m17.5 m21.4 m14.7 m25.8 m

Income tax expense

226 k336 k1 m6.3 m5.2 m6.9 m8.5 m5.9 m10.4 m

Net Income

(1.7 m)3.8 m12.7 m8.9 m7.7 m10.6 m12.9 m8.9 m15.4 m
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

20.9 m22.4 m48.2 m39 m

Accounts Receivable

24.4 m31.8 m42.8 m54.1 m

Inventories

13.9 m16.8 m26.7 m34.9 m

Current Assets

118 m220.1 m288.4 m327 m

PP&E

6.9 m9.1 m23.2 m87.8 m

Goodwill

38 m31.5 m33 m31 m

Total Assets

205.4 m338.4 m423.9 m550.4 m

Accounts Payable

7.7 m10.4 m9.4 m20.6 m

Current Liabilities

30.4 m39.3 m46.5 m69.6 m

Total Liabilities

98.3 m

Additional Paid-in Capital

436.1 m465 m508.6 m566 m

Retained Earnings

(250.9 m)(137.2 m)(99.1 m)(47 m)

Total Equity

168.4 m291.6 m368.8 m452.1 m

Financial Leverage

1.2 x1.2 x1.1 x1.2 x
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

34.7 m17.5 m19.5 m40.4 m54.4 m53.2 m38.3 m54.7 m61.1 m

Accounts Receivable

22.8 m23.1 m28.4 m34.4 m37.1 m36.8 m41.3 m46.6 m50.2 m

Inventories

13.9 m13.4 m15.4 m21.2 m23 m25.5 m29.1 m31.5 m32.1 m

Current Assets

127.2 m135.3 m160.6 m244.1 m265.4 m281.7 m300.3 m319.9 m333.4 m

PP&E

6.7 m7.4 m7.6 m10.2 m11.4 m15 m26 m50.2 m60.9 m

Goodwill

37.7 m36.9 m35.3 m32.2 m32.7 m31.7 m32.3 m32.6 m30.6 m

Total Assets

206.2 m215.5 m240.8 m352 m373.4 m391.6 m429.3 m474.9 m501 m

Accounts Payable

6.8 m7.6 m8.2 m8.6 m8.8 m8.8 m8.4 m14.1 m14.6 m

Current Liabilities

29 m27.1 m31.4 m36.3 m34.5 m37.7 m43.2 m51.9 m58.9 m

Additional Paid-in Capital

441.3 m447.4 m457.9 m474.5 m489.5 m496 m520.8 m536.9 m546.8 m

Retained Earnings

(252.6 m)(248.8 m)(236.1 m)(128.4 m)(120.6 m)(110.1 m)(86.2 m)(77.3 m)(61.9 m)

Total Equity

170.4 m175.5 m195.7 m308.1 m331.1 m345.5 m377.3 m398.4 m417.4 m

Financial Leverage

1.2 x1.2 x1.2 x1.1 x1.1 x1.1 x1.1 x1.2 x1.2 x
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

7.4 m113.7 m38.1 m52.1 m

Depreciation and Amortization

2.8 m3.3 m6.2 m

Accounts Receivable

(1.3 m)(8 m)(11 m)(11.6 m)

Inventories

(622 k)(7 m)(11 m)(12.3 m)

Accounts Payable

(54 k)3.4 m(2.6 m)7.6 m

Cash From Operating Activities

23.5 m43.3 m76.8 m115.1 m

Purchases of PP&E

(2.8 m)(5.2 m)(15.6 m)(50.4 m)

Cash From Investing Activities

(22.3 m)(49.9 m)(57.7 m)(126.3 m)

Cash From Financing Activities

9.6 m9.5 m7.2 m3.9 m

Income Taxes Paid

1.3 m1.2 m848 k1.4 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(1.7 m)3.8 m12.7 m8.9 m7.7 m10.6 m12.9 m8.9 m15.4 m

Accounts Receivable

22.8 m23.1 m28.4 m34.4 m37.1 m36.8 m41.3 m46.6 m50.2 m

Inventories

13.9 m13.4 m15.4 m21.2 m23 m25.5 m29.1 m31.5 m32.1 m

Accounts Payable

6.8 m7.6 m8.2 m8.6 m8.8 m8.8 m8.4 m14.1 m14.6 m
USDY, 2017

Revenue/Employee

596.1 k

Financial Leverage

1.2 x

ABIOMED Market Value History

ABIOMED Median Salaries

Source: 15 public H-1B filings from ABIOMED

Traffic Overview of ABIOMED

ABIOMED Online and Social Media Presence

ABIOMED News and Updates

UK-based ALung Technologies closes $36 million Series C financing

UK-based ALung Technologies, which develops technologies for patients suffering from respiratory failure, has closed a $36 million Series C financing round. The round was led by Philips and UPMC, with participation from new and existing investors including Abiomed, The Accelerator Fund, Allos Ventur…

ABIOMED Company Life and Culture

You may also be interested in